Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ALDX
ALDX logo

ALDX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Aldeyra Therapeutics Inc (ALDX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.960
1 Day change
7.10%
52 Week Range
6.170
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, Aldeyra Therapeutics Inc (ALDX) does not present a compelling buy opportunity for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. While the stock has shown recent price momentum, the lack of significant positive catalysts, financial data, or strong trading signals suggests it is better to hold off on this investment for now.

Technical Analysis

The MACD histogram is positive and expanding (0.0299), indicating bullish momentum. RSI_6 is at 78.912, which is in the neutral zone but approaching overbought levels. Moving averages are converging, suggesting no clear trend. Key resistance levels are at 1.931 and 2.019, while support levels are at 1.644 and 1.556.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low Put-Call Ratios indicate a bullish sentiment in the options market. However, implied volatility is high (262.37%), suggesting significant risk.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • The stock has an 80% chance to increase by 4.6% in the next day, 8.69% in the next week, and 34.27% in the next month based on similar candlestick patterns. Options sentiment is moderately bullish.

Neutral/Negative Catalysts

  • No recent news or significant trading trends from hedge funds or insiders. No financial data or valuation metrics are available. Congress trading data is absent, and there are no recent SwingMax or AI Stock Picker signals.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes provided.

Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
Wall Street analysts forecast ALDX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.830
sliders
Low
9
Averages
9.5
High
10
Current: 1.830
sliders
Low
9
Averages
9.5
High
10
H.C. Wainwright
Matthew Caufield
Buy -> Neutral
downgrade
$10 -> $2
AI Analysis
2026-03-18
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$10 -> $2
AI Analysis
2026-03-18
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from the FDA related to reproxalap for the topical treatment of the signs and symptoms of dry eye disease. The firm reduced its probability of success for reproxalap from 75% to 40% and downgraded Aldeyra.

People Also Watch